Within the KRAS G12R mutated group (n = 23), patients with cancers harboring PI3K pathway alterations (n = 6) vs. none (n = 17) were more likely to have metastatic disease at diagnosis (P = .098), and to have received both FOLFIRINOX and gemcitabine/nab-paclitaxel during their disease course (P = .045) (Supplementary Table S2). Here, KRAS is linked to cancer.